Immunomodulatory antibody therapy of Cancer: The closer, the better

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.

Original languageEnglish (US)
Pages (from-to)944-946
Number of pages3
JournalClinical Cancer Research
Volume21
Issue number5
DOIs
StatePublished - Mar 1 2015

Fingerprint

Immunomodulation
Antibodies
Neoplasms
Therapeutic Uses
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunomodulatory antibody therapy of Cancer : The closer, the better. / Dronca, Roxana S; Dong, Haidong M.

In: Clinical Cancer Research, Vol. 21, No. 5, 01.03.2015, p. 944-946.

Research output: Contribution to journalArticle

@article{0b31f3dbd0cd4b8e85f38161545bcc93,
title = "Immunomodulatory antibody therapy of Cancer: The closer, the better",
abstract = "Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.",
author = "Dronca, {Roxana S} and Dong, {Haidong M}",
year = "2015",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-14-2111",
language = "English (US)",
volume = "21",
pages = "944--946",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Immunomodulatory antibody therapy of Cancer

T2 - The closer, the better

AU - Dronca, Roxana S

AU - Dong, Haidong M

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.

AB - Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.

UR - http://www.scopus.com/inward/record.url?scp=84929469144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929469144&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-2111

DO - 10.1158/1078-0432.CCR-14-2111

M3 - Article

C2 - 25351746

AN - SCOPUS:84929469144

VL - 21

SP - 944

EP - 946

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -